^
Association details:
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
Title:

MMP9 Expression Correlates With Cisplatin Resistance in Small Cell Lung Cancer Patients

Published date:
04/01/2022
Excerpt:
Multivariate results showed that MMP-High could be used as an independent predictor of the prognosis of SCLC after cisplatin treatment (HR = 0.216, p = 0.00153; HR = 0.352; p = 0.0199)….The KM curve shows that MMP9-High is related to significantly prolonged OS in patients with SCLC...In this study, we identified that MMP9-High could be potentially considered a novel biomarker used to ascertain the improved prognosis of SCLC patients after cisplatin treatment.
DOI:
10.3389/fphar.2022.868203